hotspot -WSS

hotspot

author：comprehensive 2025-09-27 21:55:04 - browse：851

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： State of the Union pitch: Bigger Medicare drug price negotiations

WSS

Why failed clinical trials don’t always spell doom for a new drug

How to use technology to prevent future drug shortages

Lack of health data on LGBTQ+ people has serious consequences

NIH trials fail to test meaningful long Covid therapies, experts say

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Wegovy trial has doctors encouraged over new possibilities

focus

hotspot

focus

Wildfire smoke exposes gaps in outdoor worker protections

Drastic changes should bring profitability, startup health insurers say

The cancer drug shortage isn’t new — and neither are the solutions

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Microsoft's Peter Lee: Generative AI could help doctors be more human

Affirmative action in medical school literally saved lives

Stem cell biologist probes earliest stages of human development

entertainment

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Families look for replacement for GSK asthma drug Flovent

Anavex keeps shifting the goalposts in its clinical trials

A new approach to psychiatric drug development

FDA panel issues narrow recommendation for Covid vaccine booster doses

Wegovy’s successful heart trial raises vital question about weight loss

knowledge

Wikipedia

hotspot

explore